Hello I’ve just received another letter this time from the ms nurse & neurology service.
Just going to point out some of the info, some of you probably already know and may have received this letter. Thought I’d share on here anyway.
Ms patients in the vulnerable category that require shielding are as followed:
Those who have significant breathing or swallowing difficulties. Those who have received lemtrada or mavenclad in the past 3 months. Those who do not fulfil the criteria for extremely vulnerable. Treatment with mavenclad and lemtrada within the past 6 months. Treatment with Gilenya. Ocrevus within the past 12 months.
Avonex, rebif, plegridy, betaferon, extavia, coxapone, aubagio, tecfidera and tysabri treatments do not significantly increase the risk of systemic viral infections.
Gilenya and Ovrevus: risk of viral infections is moderately increased.
If you have had 2 cycles of cladribine or alemtuzumab and the latest round was within 3 months the risk of viral infections is significantly increased.
MRI scans will have a longer than normal wait for scans to be performed. Blood monitoring for patients who are prescribed DMTs may reduce the frequency of tests. Where blood tests are essential your ms team will facilitate this in an outpatient setting.
Browse categories and add by clicking on them
You can remove current categories below by clicking the ‘x’.